Study to Evaluate the Effectiveness of the Personal Pap Smear Device™ for Collection of Cervical Cells
Launched by MOREHOUSE SCHOOL OF MEDICINE · Jan 19, 2024
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new device called the Personal Pap Smear Device™ to see how well it collects cervical cell samples for testing compared to a standard tool called the Rover Cervex-Brush. The goal is to find out if the new device is just as effective in helping detect cervical cancer, which is important for women's health.
To participate, women aged 21 to 65 who are in good health can join the study, but some will not be eligible. For example, if a woman is currently menstruating, pregnant, or has had certain medical treatments, she won't be able to take part. Participants will have the opportunity to use the new device and provide feedback on their experience. It's important for anyone considering joining the trial to know that they will be helping researchers learn more about cervical cancer screening, which can ultimately benefit many women in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Adult women, aged 21-65 years old.
- • Do not have any medical or psychiatric condition affecting the ability to give voluntary informed consent.
- • Be able to read and understand English
- Exclusion Criteria:
- • Participants currently on menses
- • Inability to provide Informed Consent
- • Previous total hysterectomy
- • History of radiation treatment for cervical cancer
- • Pregnancy
- • Medical condition that interferes with conduct of study, in investigator's opinion
- • Evidence of active cervical infection requiring treatment
- • Known bleeding diathesis
About Morehouse School Of Medicine
Morehouse School of Medicine (MSM) is a distinguished institution dedicated to improving health outcomes through education, research, and community service. As a leading academic medical center, MSM focuses on addressing health disparities and enhancing healthcare delivery, particularly in underserved populations. The institution is committed to advancing medical knowledge and innovation through rigorous clinical trials, fostering collaborations that bridge science and community health. With a strong emphasis on training the next generation of healthcare leaders, MSM integrates its research initiatives with a mission to promote equity and access in healthcare for all.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Regina K Leonis, MD, MD
Principal Investigator
Morehouse School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported